[1] SURREY E S, SCHOOLCRAFT W B. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques[J]. Fertil Steril, 2000,73(4):667-676.
[2] THUM M Y, ABDALLA H I, TAYLOR D. Relationship between women's age and basal follicle-stimulating hormone levels with aneuploidy risk in in vitro fertilization treatment[J]. Fertil Steril, 2008,90(2):315-321.
[3] GOMES L M, CANHA ADOS S, DZIK A, et al. The age as a predictive factor in in vitro fertilization cycles [J]. Rev Bras Ginecol Obstet, 2009, 31(5):230-234.
[4] YAN J, WU K, TANG R, et al. Effect of maternal age on the outcomes of in vitro fertilization and embryo transfer (IVF-ET)[J]. Sci China Life Sci, 2012, 55(8):694-698.
[5] GRIFFITHS A, DYER S M, LORD S J, et al. A cost-effectiveness analysis of in vitro fertilization by maternal age and number of treatment attempts[J]. Hum Reprod, 2010, 25(4):924-931.
[6] VINCENT-ROHFRITSCH A, LE RAY C, ANSELEM O, et al. Pregnancy in women aged 43 years or older: maternal and perinatal risks[J]. Gynecol Obstet Biol Reprod, 2012, 41(5):468-475.
[7] LIU K, CASE A. Advanced reproductive age and fertility [J]. J Obstet Gynaecol Can, 2011, 33(11):1165-1175.
[8] WATT A H, LEGEDZA A T, GINSBURG E S, et al. The prognostic value of age and follicle-stimulating hormone levels in women over forty years of age undergoing in vitro fertilization[J]. J Assist Reprod Genet, 2000, 17(5):264-268.
[9] FRAGOULI E, WELLS D, DELHANTY D. Chromosome abnormalities in the human oocyte[J]. Cytogenet Genome Res, 2011,133(2-4):107-118.
[10] SANDALINAS M, MARQUEZ C, MUNNE S. Spectral karyotyping of fresh, non-inseminated oocytes [J]. Mol Hum Reprod, 2002, 8(6): 580-585.
[11] KULIEV A, CIESLAK J, ILKEVITCH Y, et al. Chromosomal abnormalities in a series of 6,733 human oocytes in preimplantation diagnosis for age-related aneuploidies[J]. Reprod Biomed Online, 2003, 6(1): 54-59.
[12] PELLESTOR F, ANDREO B, ARNAL F, et al. Maternal aging and chromosomal abnormalities: new data drawn from in vitro unfertilized human oocytes[J]. Hum Genet, 2003, 112(2):195-203.
[13] HASSOLD T, HALL H, HUNT P. The origin of human aneuploidy: where we have been, where we are going [J]. Hum Mol Genet, 2007,16(Spec No. 2):R203-R208.
[14] FRAGOULI E, ESCALONA A, GUTIERREZ-MATEO C, et al. Comparative genomic hybridization of oocytes and first polar bodies from young donors[J]. Reprod Biomed Online, 2009,19(2): 228-237.
[15] FRAGOULI E, KATZ-JAFFE M, ALFARAWATI S, et al. Comprehensive chromosome screening of polar bodies and blastocysts from couples experiencing repeated implantation failure [J]. Fertil Steril, 2010,94(3): 875-887.
[16] ZENZES M T, CASPER R F. Cytogenetics of human oocytes, zygotes and embryos after in vitro fertilisation[J]. Hum Genet, 1992, 88(4): 367-375.
[17] ANGELL R R. Predivision in human oocytes at meiosis I: a mechanism for trisomy formation in man [J]. Hum Genet, 1991, 86(4): 383-387.
[18] GRANDE M, BORRELL A, GARCIA-POSADA R, et al. The effect of maternal age on chromosomal anomaly rate and spectrum in recurrent miscarriage[J]. Hum Reprod, 2012, 27(10):3109-3117.
[19] CHEN X, PROSSER R, SIMONETTI S, et al. Rearranged mitochondrial genomes are present in human oocytes[J]. Am J Hum Genet, 1995,57(2):239-247.
[20] KEEFE D L, NIVEN-FAIRCHILD T, POWELL S, et al. Mitochondrial deoxyribonucleic acid deletions in oocytes and reproductive aging in women[J]. Fertil Steril,1995,64(3):577-583.
[21] BARTMANN A K, ROMAO G S, RAMOS EDA S, et al. Why do older women have poor implantation rates? A possible role of the mitochondria[J]. J Assist Reprod Genet, 2004, 21(3):79-83.
[22] WILDING M, DI MATTEO L, DALE B. The maternal age effect: a hypothesis based on oxidative phosphorylation[J]. Zygote, 2005, 13(4):317-323.
[23] SEIFER D B, DEJESUS V, Hubbard K. Mitochondrial deletions in luteinized granulosa cells as a function of age in women undergoing in vitro fertilization[J]. Fertil Steril, 2002, 78(5):1046-1048.
[24] COHEN J, SCOTT R, ALIKANI M, et al. Ooplasmic transfer in mature human oocytes [J]. Mol Hum Reprod, 1998,4(3):269-280.
[25] TAKEUCHI T, NERI Q V, KATAGIRI Y, et al. Effect of treating induced mitochondrial damage on embryonic development and epigenesis[J]. Biol Reprod, 2005,72(3):584-592.
[26] BENTOV Y, ESFANDIARI N, BURSTEIN E, et al. The use of mitochondrial nutrients to improve the outcome of infertility treatment in older patients [J]. Fertil Steril, 2010,93(1):272-275.
[27] VAN ROOIJ I A, BANCSI L F, BROEKMANS F J, et al. Women older than 40 years of age and those with elevated follicle-stimulating hormone levels differ in poor response rate and embryo quality in in vitro fertilization[J]. Fertil Steril, 2003, 79(3):482-488.
[28] CHUANG C C, CHEN C D, CHAO K H, et al. Age is a better predictor of pregnancy potential than basal follicle-stimulating hormone levels in women undergoing in vitro fertilization [J]. Fertil Steril, 2003,79(1):63-68.
[29] CHECK J H, KATSOFF B, BRASILE D, et al. Pregnancy outcome following in vitro fertilization-embryo transfer (IVF-ET) in women of more advanced reproductive age with elevated serum follicle stimulating hormone (FSH) levels[J]. Clin Exp Obstet Gynecol, 2008, 35(1):13-15.
[30] MUTLU M F, ERDEM M, ERDEM A, et al. Antral follicle count determines poor ovarian response better than anti-Müllerian hormone but age is the only predictor for live birth in in vitro fertilization cycles[J]. J Assist Reprod Genet, 2013, 30(5):657-665.
[31] KISSIN D M, KULKAMI A D, KUSHNIR V A, et al. Number of embryos transferred after in vitro fertilization and good perinatal outcome [J]. Obstet Gynecol,2014, 123(2):239-247.
[32] Practice Committee of the American Society for Reproductive Medicine and the Practice Committee of the Society for Assisted Reproductive Technology. Criteria for number of embryos to transfer: a committee opinion[J]. Fertil Steril, 2013,99(1):44-46.
[33] KAUR P, SWARANKAR M L, MAHESHWARI M, et al. A comparative study between cleavage stage embryo transfer at day 3 and blastocyst stage transfer at day 5 in in vitro fertilization/intra-cytoplasmic sperm injection on clinical pregnancy rates[J].J Hum Reprod Sci, 2014, 7(3):194-197.
[34] FERNANDEZ-SHAW S, CERCAS R, BRANA C, et al. Ongoing and cumulative pregnancy rate after cleavage-stage versus blastocyst-stage embryo transfer using vitrification for cryopreservation: impact of age on the results[J]. J Assist Reprod Genet, 2015,32(2):177-184.
[35] ORVIETO R, HOMBURG R, MELTCER S, et al. GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a priori[J]. Fertil Steril, 2009, 91(4 Suppl):1378-1380.
[36] 章晓梅.高龄不育妇女在体外受精一胚胎移植中的降调节[J].生殖医学杂志,2007,16(5):308-310. ZHANG Xiao-mei. Down regulation in older women undergoing IVF-ET [J]. Journal of Reproductive Medicine, 2007,16(5):308-310.(in Chinese)
[37] 倪 郝,陈雷宁,陈思梅,等. GnRH-a长方案和GnRH-ant方案在高龄患者IVF-ET中应用效果的比较[J]. 中国妇产科临床杂志, 2011,12(6): 406-409. NI Hao, CHEN Lei-ning, CHEN Si-mei, et al. Comparison of GnRH-agonist long protocol with GnRH-antagonist protocol in women with advanced reproductive-age undergoing IVF-ET[J]. Chinese Journal of Clinical Obstetetrics Gynecology, 2011,12(6): 406-409. (in Chinese)
[38] LUDWIG M, KATALINIC A, DIEDRICH K. Use of bGnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis[J]. Arch Gynecol Obstet, 2001,265(4):175-182.
[39] FRANCO J G, BARUFFI R L, MAURI A L, et al. GnRH agonist versus GnRH antagonist in poor ovarian responders: a meta-analysis[J]. Reprod Biomed Online, 2006, 13(5):618-627.
[40] CHECK J H, CHOE J K, COHEN R, et al. A study to determine the efficacy of controlled ovarian hyperstimulation regimen using a gonadotropin releasing hormone agonist versus antagonist in women of advanced reproductive age with varying degrees of oocyte reserve on outcome following in vitro fertilization-embryo transfer[J]. Clin Exp Obstet Gynecol, 2013, 40(2):191-192.